References
(1) S Seiwerth, R Rucman, B Turkovic, M Sever, et al (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing – Current Pharmaceutical Design, 2018, Volume 24 (Issue 18), Pages 1972-1989.
(2) D Gwyer, N M Wragg, and S L Wilson (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing – Cell and Tissue Research, 2019 Aug, Volume 377 (Issue 2), Pages 153-159.
(3) N Vasireddi, H Hahamyan, M J Salata, et al (2025) Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review – HSS Journal, 2025 Jul 31, 15563316251355551.
(4) S Seiwerth, M Milavic, J Vukojevic, S Gojkovic, et al (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing – Frontiers in Pharmacology, 2021 Jun 29, Volume 12, Page 627533.
(5) J Vukojevic, M Milavić, D Perović, S Ilić, et al (2022). Pentadecapeptide BPC 157 and the central nervous system – Neural Regeneration Research, 2022 Mar, Volume 17 (Issue 3), Pages 482-487.
(6) P Sikiric, S Seiwerth, R Rucman, B Turkovic, et al (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract – Current Pharmaceutical Design, 2011, Volume 17 (Issue 16), Pages 1612-32.
(7) M J Hsieh, H T Liu, C N Wang, H Y Huang, et al (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation – Journal of Molecular Medicine (Berlin, Germany), 2017 Mar, Volume 95 (Issue 3), Pages 323-333.